"Valsartan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.
| Descriptor ID |
D000068756
|
| MeSH Number(s) |
D03.383.129.617.850 D12.125.070.950.550 D12.125.142.930.500
|
| Concept/Terms |
Valsartan- Valsartan
- N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
|
Below are MeSH descriptors whose meaning is more general than "Valsartan".
Below are MeSH descriptors whose meaning is more specific than "Valsartan".
This graph shows the total number of publications written about "Valsartan" by people in this website by year, and whether "Valsartan" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 3 | 3 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 3 | 4 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Valsartan" by people in Profiles.
-
Sacubitril/valsartan use patterns among older adults with heart failure in clinical practice: a population-based cohort study of >25?000 Medicare beneficiaries. Eur J Heart Fail. 2022 Sep; 24(9):1506-1515.
-
Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. JAMA Cardiol. 2021 12 01; 6(12):1415-1423.
-
Adherence to Evidence-Based Therapies in Heart Failure: Deepening the Implementation Divide. JACC Heart Fail. 2021 12; 9(12):887-889.
-
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. Eur J Heart Fail. 2021 09; 23(9):1518-1524.
-
Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization. J Card Fail. 2021 09; 27(9):1027-1030.
-
Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. JACC Heart Fail. 2020 10; 8(10):859-866.
-
Improving physical activity and exercise capacity in heart failure. Taking the first step is always the hardest. Eur J Heart Fail. 2020 09; 22(9):1734-1736.
-
Angiotensin-neprilysin inhibition in de novo heart failure - starting off strong. Eur J Heart Fail. 2020 02; 22(2):313-314.
-
Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations? Eur J Heart Fail. 2019 11; 21(11):1398-1401.
-
In-hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time. Eur J Heart Fail. 2019 08; 21(8):1008-1011.